

Record: 1

Title: Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

Author(s): Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL

Contact Information: Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia.
kruenator@gmail.com

Review Group(s): Cochrane Drugs and Alcohol Group Trials in the Group's Specialized Register

Source: Lancet 2011 Apr 377 9776, 1506 (1506-13)

MEDLINE Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Record Status: This record is new this issue.

Abstract: BACKGROUND: Opioid dependence is associated with low rates of treatment-seeking, poor adherence to treatment, frequent relapse, and major societal consequences. We aimed to assess the efficacy, safety, and patient-reported outcomes of an injectable, once monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) for treatment of patients with opioid dependence after detoxification. METHODS: We did a double-blind, placebo-controlled, randomised, 24-week trial of patients with opioid dependence disorder. Patients aged 18 years or over who had 30 days or less of inpatient detoxification and 7 days or more off all opioids were enrolled at 13 clinical sites in Russia. We randomly assigned patients (1:1) to either 380 mg XR-NTX or placebo by an interactive voice response system, stratified by site and gender in a centralised, permuted-block method. Participants also received 12 biweekly counselling sessions. Participants, investigators, staff, and the sponsor were masked to treatment allocation. The primary endpoint was the response profile for confirmed abstinence during weeks 5–24, assessed by urine drug tests and self report of non-use. Secondary endpoints were self-reported opioid-free days, opioid craving scores, number of days of retention, and relapse to physiological opioid dependence. Analyses were by intention to treat. This trial is registered at ClinicalTrials.gov,

NCT00678418.FINDINGS: Between July 3, 2008, and Oct 5, 2009, 250 patients were randomly assigned to XR-NTX (n=126) or placebo (n=124). The median proportion of weeks of confirmed abstinence was 90.0% (95% CI 69.9–92.4) in the XR-NTX group compared with 35.0% (11.4–63.8) in the placebo group (p=0.0002). Patients in the XR-NTX group self-reported a median of 99.2% (range 89.1–99.4) opioid-free days compared with 60.4% (46.2–94.0) for the placebo group (p=0.0004). The mean change in craving was –10.1 (95% CI –12.3 to –7.8) in the XR-NTX group compared with 0.7 (–3.1 to 4.4) in the placebo group (p<0.0001). Median retention was over 168 days in the XR-NTX group compared with 96 days (95% CI 63–165) in the placebo group (p=0.0042). Naloxone challenge confirmed relapse to physiological opioid dependence in 17 patients in the placebo group compared with one in the XR-NTX group (p<0.0001). XR-NTX was well tolerated. Two patients in each group discontinued owing to adverse events. No XR-NTX-treated patients died, overdosed, or discontinued owing to severe adverse events.INTERPRETATION: XR-NTX represents a new treatment option that is distinct from opioid agonist maintenance treatment. XR-NTX in conjunction with psychosocial treatment might improve acceptance of opioid dependence pharmacotherapy and provide a useful treatment option for many patients.FUNDING: Alkermes.

Medical Subject Headings Adult

(MeSH): Female

Humans

Male

Delayed-Action Preparations

Double-Blind Method

Drug Administration Schedule

HIV Seropositivity/complications

Injections

Naltrexone/adverse effects

Narcotic Antagonists/adverse effects

Opioid-Related Disorders/virology

Substance Abuse Detection

Naltrexone/*administration & dosage

Narcotic Antagonists/*administration & dosage

Opioid-Related Disorders/*rehabilitation

MEDLINE UI: 21529928

Cochrane Source Information: This document should be cited as: Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial 2011 Apr (*The Cochrane Controlled Trials Register (CTTR/CENTRAL)*). In: *The Cochrane Library*, Issue 1, 2012. Oxford: Update Software. Updated quarterly.

Accession Number: CN-00788703

Database: Cochrane Central Register of Controlled Trials